Ardelyx Shares Rally Premarket on FDA Approval of Xphozah
By Colin Kellaher
Shares of Ardelyx rose sharply in premarket trading Wednesday after the biopharmaceutical company finally won U.S. Food and Drug Administration approval of its Xphozah drug for kidney disease.
After the closing bell on Tuesday, the Waltham, Mass., biopharmaceutical company said the FDA approved Xphozah to reduce serum phosphorus in adults with chronic kidney disease who are on dialysis.
The FDA in 2021 rejected Ardelyx's initial application for approval of Xphozah, but the company appealed, and an FDA advisory committee late last year voted that the drug's benefits outweigh its risks, and the agency in May accepted Ardelyx's resubmitted application for Xphozah.
Ardelyx said the commercial launch for Xphozah is underway, with the drug expected to be available next month.
Ardelyx shares, which closed Tuesday at $3.45, were recently up more than 16% to $4.02 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 18, 2023 08:15 ET (12:15 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now